ClinicalTrials.gg
CompletedNCT01641081Updated Feb 28, 2017Results posted

Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma

A Phase 2 interventional study of Formoterol Fumarate in the Pressair DPI, Low Dose and Formoterol Fumarate in the Pressair DPI, High Dose in Asthma, sponsored by AstraZeneca. Completed at 29 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-28.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
174
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 86 studies testing formoterol in Asthma — 2 open to participants now, 2 under way, 2 of them phase 3. formoterol · Asthma.

Enrollment
40th of 85
174 · median 100
Started
2012
with 2 others
Phase 2
17 of 86
none open now
Registered
60th of 86
by date
Lead sponsor
25 of 86
AstraZeneca

Among the 86 studies testing formoterol in Asthma, this one is the 40th largest by enrollment of the 85 interventional ones that give a count, is one of 3 that started in 2012, is one of 17 in phase 2, and was the 60th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

2 of the 86 studies testing formoterol in Asthma are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About formoterol

formoterol: first FDA approval 2001 (FORADIL), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies testing formoterol in Asthma, or all of them as a file.
02

Study summary

The purpose of this Phase II study is to evaluate efficacy and safety of inhaled formoterol fumarate in the Pressair DPI compared to the Foradil Aerolizer in patients with mild to moderate asthma.

This study will include a screening visit followed by a 4 month treatment period.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with mild-to-moderate asthma for at least 6 months prior to Visit 1 (as defined in the GINA Guidelines) which is unlikely to exacerbate during the study (e.g., due to seasonal allergen exposure).
  • Patients must be on a stable dose of Inhaled (ICS) for at least 30 days prior to Visit 1. Patients on a combination of ICS/LABA must discontinue the use of LABA and must be on a stable dose of ICS for 30 days prior to Visit 1.
  • Qualifying spirometry at Visit 1 demonstrates highest is ≤ 85% and ≥ 60% of predicted for age, height, and gender using NHANES III (NHANES 2010) when bronchodilator medications have been withheld the appropriate length of time per the List of Concomitant Medications (Appendix III)
  • Patient demonstrates reversibility with an increase in FEV1 of 12% and 200 mL after the administration of 360 µg of albuterol.
  • Highest pre-dose FEV1 at Visits 2, 4, 6, 8, and 10 must be within 25% of the qualifying FEV1 at Visit 1

Exclusion criteria

Exclusions:

  • Patients with any respiratory conditions other than mild to moderate asthma, such as , active tuberculosis, or history of interstitial lung disease
  • Patients with a severe asthma exacerbation requiring hospitalization in the previous 12 months
  • Patient is not able to withhold use of inhaled short-acting beta-agonist (SABA) for at least 6 hours prior to visit
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
174 participants (actual)

Study arms

  • Experimental
    Experimental 1

    Formoterol Fumarate in the Pressair Pressair Dry Powder Inhaler (DPI), Low Dose

    Drug: Formoterol Fumarate in the Pressair DPI, Low Dose

  • Experimental
    Experimental 2

    Formoterol fumarate in the Pressair Dry Powder Inhaler (DPI), High Dose

    Drug: Formoterol Fumarate in the Pressair DPI, High Dose

  • Active comparator
    Active Comparator 1

    Foradil Aerolizer, Low Dose

    Drug: Foradil Aerolizer, Low Dose

  • Active comparator
    Active Comparator 2

    Foradil Aerolizer, High Dose

    Drug: Foradil Aerolizer, High Dose

  • Placebo comparator
    Placebo

    Dose matched placebo

    Drug: Placebo

Interventions

  • DrugFormoterol Fumarate in the Pressair DPI, Low Dose

    Formoterol Fumarate in the Pressair DPI 6 micrograms, twice a day for 14 days

  • DrugFormoterol Fumarate in the Pressair DPI, High Dose

    Formoterol Fumarate in the Pressair DPI 12 micrograms, twice a day for 14 days

  • Foradil Aerolizer 12 micrograms, twice a day for 14 days

    Also known as: Formoterol

  • Foradil Aerolizer 24 micrograms, twice per day for 14 days

    Also known as: Formoterol

  • DrugPlacebo

    Placebo in the Pressair for 14 days

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) AUC0-6 After the Morning Dose (Day 14)

    AUC0-6 is area under the curve from time 0 to 6 hours Serial spirometry was performed at -60 min predose, at 5 (+5) and 30 (±5) min post-dose, and at 1, 2, 3, 4, and 6 hrs post-dose (±15 min) Change from baseline was baseline of each treatment period The normalized FEV1 AUC0-6 was calculated by means of the trapezoidal method, dividing the area under the curve by the corresponding time intervals

    Time frame: Baseline and up to 6 hrs post-dose (±15 min) on Day 14 of treatment

Secondary outcomes

  1. Change From Baseline in Normalized FEV1 AUC0-6 After the Morning Dose (Day 1)

    AUC0-6 is area under the curve from time 0 to 6 hours Serial spirometry was performed at -60 min predose, at 5 (+5) and 30 (±5) min post-dose, and at 1, 2, 3, 4, and 6 hrs post-dose (±15 min) Change from baseline was baseline of Period 1 The time-normalized FEV1 AUC0-6 was calculated by means of the trapezoidal method, dividing the area under the curve by the corresponding time intervals

    Time frame: Baseline and up to 6 hrs post-dose (±15 min) on Day 1 of treatment

07

Results

Posted Dec 22, 2016

Participant flow

The study was conducted in 29 study centers in the United States First patient visit was in June 2012 and last patient visit was in February 2013

Period 1
Participant flow — Period 1
MilestoneSequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6Sequence 7Sequence 8Sequence 9Sequence 10
Started18181522171919171514
Completed17181522161918141514
Not completed1000101300
Withdrew: Sponsor request (potential unblinding)0000001000
Withdrew: Protocol violation0000100100
Withdrew: Adverse event1000000200
Period 2
Participant flow — Period 2
MilestoneSequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6Sequence 7Sequence 8Sequence 9Sequence 10
Started17181522161918141514
Completed16181521161816141514
Not completed1001012000
Withdrew: Adverse event0000010000
Withdrew: Withdrawal by subject0001002000
Withdrew: Protocol violation1000000000
Period 3
Participant flow — Period 3
MilestoneSequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6Sequence 7Sequence 8Sequence 9Sequence 10
Started16181521161816141514
Completed16181421161816141414
Not completed0010000010
Withdrew: Adverse event0010000000
Withdrew: Withdrawal by subject0000000010
Period 4
Participant flow — Period 4
MilestoneSequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6Sequence 7Sequence 8Sequence 9Sequence 10
Started16181421161816141414
Completed16171420161816141414
Not completed0101000000
Withdrew: Adverse event0101000000
Period 5
Participant flow — Period 5
MilestoneSequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6Sequence 7Sequence 8Sequence 9Sequence 10
Started16171420161816141414
Completed16171220161816141414
Not completed0020000000
Withdrew: Adverse event0020000000

Outcome measures

PrimaryChange From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) AUC0-6 After the Morning Dose (Day 14)

AUC0-6 is area under the curve from time 0 to 6 hours Serial spirometry was performed at -60 min predose, at 5 (+5) and 30 (±5) min post-dose, and at 1, 2, 3, 4, and 6 hrs post-dose (±15 min) Change from baseline was baseline of each treatment period The normalized FEV1 AUC0-6 was calculated by means of the trapezoidal method, dividing the area under the curve by the corresponding time intervals

Time frame:
Baseline and up to 6 hrs post-dose (±15 min) on Day 14 of treatment
Reported as:
Least squares mean · Liters
Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) AUC0-6 After the Morning Dose (Day 14)
LitersForadil 24 μgForadil 12 μgFormoterol 12 μgFormoterol 6 μgPlacebo
Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) AUC0-6 After the Morning Dose (Day 14)0.3196 ± 0.03820.3076 ± 0.03820.2795 ± 0.03820.2726 ± 0.03810.0552 ± 0.0382
Statistical analysis
  • Foradil 24 μg vs Placebo · Mixed Models Analysis · p = <0.0001 · Least squares mean difference: 0.2644 · 95% CI 0.2353 to 0.2934Treatment and period as fixed effects, and baseline FEV1 values at each period as a covariate
  • Foradil 12 μg vs Placebo · Mixed Models Analysis · p = <0.0001 · Least squares mean difference: 0.2524 · 95% CI 0.2218 to 0.2830Treatment and period as fixed effects, and baseline FEV1 values at each period as a covariate
  • Formoterol 12 μg vs Placebo · Mixed Models Analysis · p = <0.0001 · Least squares mean difference: 0.2242 · 95% CI 0.1941 to 0.2544Treatment and period as fixed effects, and baseline FEV1 values at each period as a covariate
  • Formoterol 6 μg vs Placebo · Mixed Models Analysis · p = <0.0001 · Least squares mean difference: 0.2174 · 95% CI 0.1887 to 0.2461Treatment and period as fixed effects, and baseline FEV1 values at each period as a covariate
SecondaryChange From Baseline in Normalized FEV1 AUC0-6 After the Morning Dose (Day 1)

AUC0-6 is area under the curve from time 0 to 6 hours Serial spirometry was performed at -60 min predose, at 5 (+5) and 30 (±5) min post-dose, and at 1, 2, 3, 4, and 6 hrs post-dose (±15 min) Change from baseline was baseline of Period 1 The time-normalized FEV1 AUC0-6 was calculated by means of the trapezoidal method, dividing the area under the curve by the corresponding time intervals

Time frame:
Baseline and up to 6 hrs post-dose (±15 min) on Day 1 of treatment
Reported as:
Least squares mean · Liters
Change From Baseline in Normalized FEV1 AUC0-6 After the Morning Dose (Day 1)
LitersForadil 24 μgForadil 12 μgFormoterol 12 μgFormoterol 6 μgPlacebo
Change From Baseline in Normalized FEV1 AUC0-6 After the Morning Dose (Day 1)0.3544 ± 0.01960.3068 ± 0.01980.2712 ± 0.01970.2204 ± 0.01970.0306 ± 0.0198

Adverse events

Collected over Day 14±1 of the final treatment period (Period 5). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Foradil 24 μg—0/167 (0%)10/167 (6%)
Foradil 12 μg—2/163 (1.2%)2/163 (1.2%)
Formoterol 12 μg—0/164 (0%)2/164 (1.2%)
Formoterol 6 μg—0/166 (0%)1/166 (0.6%)
Placebo—0/165 (0%)0/165 (0%)
Most frequent serious events
Most frequent serious events
EventForadil 24 μgForadil 12 μgFormoterol 12 μgFormoterol 6 μgPlacebo
Ankle fractureInjury, poisoning and procedural complications0/1671/1630/1640/1660/165
OsteoarthritisMusculoskeletal and connective tissue disorders0/1671/1630/1640/1660/165
Most frequent other events
Most frequent other events
EventForadil 24 μgForadil 12 μgFormoterol 12 μgFormoterol 6 μgPlacebo
TremorNervous system disorders10/1672/1632/1641/1660/165

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Overall Study Population
Mean45.4 ± 13.2
Gender
Gender(Participants)Overall Study Population
Female91
Male83
08

Study locations

29 sites
  • Forest Investigative Site 909
    Phoenix, Arizona 85006, United States
  • Forest Investigative Site 2066
    Encinitas, California 92024, United States
  • Forest Investigative Site 1624
    Los Angeles, California 90025, United States
  • Forest Investigative Site 1995
    Mission Viejo, California 92691, United States
  • Forest Investigative Site 1347
    San Jose, California 95117, United States
  • Forest Investigative Site 1996
    Centennial, Colorado 80112, United States
  • Forest Investigative Site 1137
    Colorado Springs, Colorado 80907, United States
  • Forest Investigative Site 1998
    Denver, Colorado 80230, United States
  • Forest Investigative Site 2047
    Tampa, Florida 33613, United States
  • Forest Investigative Site 1536
    Louisville, Kentucky 40215, United States
  • Forest Investigative Site 1333
    Baltimore, Maryland 21236, United States
  • Forest Investigative Site 1431
    North Dartmouth, Massachusetts 02747, United States
  • Forest Investigative Site 2041
    Minneapolis, Minnesota 55402, United States
  • Forest Investigative Site 1599
    Saint Louis, Missouri 63141, United States
  • Forest Investigative Site 1609
    Bellevue, Nebraska 68123, United States
  • Forest Investigative Site 1999
    Skillman, New Jersey 08558, United States
  • Forest Investigative Site 1153
    Raleigh, North Carolina 27607, United States
  • Forest Investigative Site 1134
    Canton, Ohio 44718, United States
  • Forest Investigative Site 1806
    Cincinnati, Ohio 45231, United States
  • Forest Investigative Site 1176
    Oklahoma City, Oklahoma 73120, United States
  • Forest Investigative Site 2043
    Medford, Oregon 97504, United States
  • Forest Investigative Site 1580
    Portland, Oregon 97202, United States
  • Forest Investigative Site 2025
    Charleston, South Carolina 29407, United States
  • Forest Investigative Site 1155
    Dallas, Texas 75231, United States
  • Forest Investigative Site 1332
    El Paso, Texas 79903, United States
  • Forest Investigative Site 1370
    New Braunfels, Texas 78130, United States
  • Forest Investigative Site 1699
    San Antonio, Texas 78229, United States
  • Forest Investigative Site 2011
    Seattle, Washington 98115, United States
  • Forest Investigative Site 1997
    Madison, Wisconsin 53792, United States
09

References and documents

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2012, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2016, 3 years 10 months after primary completion. A results delay was requested in Feb 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2012
First posted
Jul 16, 2012
Start
Jun 2012
Primary completionActual
Feb 2013
CompletionActual
Feb 2013
Results delay requested
Feb 13, 2013
Results first posted
Dec 22, 2016
Last update
Feb 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01641081
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 16, 2012
Start date
Jun 2012
Primary completion
Feb 2013
Completion
Feb 2013
Results posted
Dec 22, 2016
Last update
Feb 28, 2017

Study contacts

Esther Garcia, MD
study director · AstraZeneca

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Formoterol

Start the discussion